Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Greater Cannabis CO Inc (GCAN)

Greater Cannabis CO Inc (GCAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Greater Cannabis CO Inc

www.gammacan.com

Description:

Gammacan International, Inc. was incorporated under the laws of the state of Delaware on October 6, 1998 under the name of San Jose International, Inc. On August 19, 2004, the Company changed the name of its company to Gammacan International, Inc. in the State of Delaware. With the acquisition of the Intellectual Property, the Company is now focused on the commercialization of an anti-cancer immunotherapy that appears to be effective in reducing the metastatic spread of a wide range of cancers. The Company's proposed treatment will be based on intravenous immunoglobulin or IVIG, a safe, minimally-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases, and replace the antibodies in people who are unable to produce them. The Company's initial focus over the next several years is to demonstrate efficacy of IVIG cancer immunotherapy in human clinical trials. IVIG immunotherapy will require regulatory approval before being commercially marketed for human therapeutic use. Clinical trials generally include three phases that together may take several years to complete. Phase 1 clinical studies are primarily conducted to establish safety. Phase 2 studies are designed to determine preliminary efficacy. Phase 3 studies are conducted to optimize therapeutic efficacy in a statistical manner at the levels of optimal dose, method of delivery into the body or route, and schedule of administration. Once clinical trials are completed successfully, products may receive regulatory approval.

Key Statistics

Overview:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K
Short Volume Ratio 1.00

Growth:

1-Year Return -14.29%
3-Year Return -92.94%
5-Year Return -99.50%

Per-Share Information:

Latest Earnings Date N/A
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Dividend Payout Ratio 0.00%

GCAN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 0.00
Price/Earnings to Growth 0.00
Return-on-Equity % -2.13%
Return-on-Assets % -1.65%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow 0.00
Price/Book 0.00
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar